Paxman AB (publ) (PAX.ST)
SEK 65.0
(0.0%)
SEK 65.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -11.41 Million SEK | 45.94% |
| 2022 | -21.1 Million SEK | 61.7% |
| 2021 | -55.11 Million SEK | -223.42% |
| 2020 | 44.65 Million SEK | 49.6% |
| 2019 | 29.84 Million SEK | 142.14% |
| 2018 | 12.32 Million SEK | 320.24% |
| 2017 | -5.59 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -12.29 Million SEK | -7.72% |
| 2024 Q2 | -20.06 Million SEK | -63.27% |
| 2023 Q4 | -11.41 Million SEK | -106.57% |
| 2023 Q3 | -5.52 Million SEK | 45.1% |
| 2023 FY | -11.41 Million SEK | 45.94% |
| 2023 Q1 | -12.78 Million SEK | 39.41% |
| 2023 Q2 | -10.06 Million SEK | 21.32% |
| 2022 Q3 | -28.86 Million SEK | 33.08% |
| 2022 FY | -21.1 Million SEK | 61.7% |
| 2022 Q1 | -46.25 Million SEK | 16.07% |
| 2022 Q4 | -21.1 Million SEK | 26.87% |
| 2022 Q2 | -43.12 Million SEK | 6.76% |
| 2021 Q3 | 9.92 Million SEK | 159.64% |
| 2021 Q4 | -55.11 Million SEK | -655.51% |
| 2021 FY | -55.11 Million SEK | -223.42% |
| 2021 Q1 | -2.94 Million SEK | -106.59% |
| 2021 Q2 | 3.82 Million SEK | 229.83% |
| 2020 FY | 44.65 Million SEK | 49.6% |
| 2020 Q3 | 41.97 Million SEK | 9.76% |
| 2020 Q4 | 44.65 Million SEK | 6.39% |
| 2020 Q2 | 38.23 Million SEK | 7.83% |
| 2020 Q1 | 35.46 Million SEK | 18.8% |
| 2019 Q4 | 29.84 Million SEK | 8.8% |
| 2019 Q3 | 27.43 Million SEK | 22.09% |
| 2019 Q1 | 18.49 Million SEK | 50.03% |
| 2019 FY | 29.84 Million SEK | 142.14% |
| 2019 Q2 | 22.47 Million SEK | 21.5% |
| 2018 Q3 | 8.23 Million SEK | 72.36% |
| 2018 FY | 12.32 Million SEK | 320.24% |
| 2018 Q1 | -3.78 Million SEK | 32.36% |
| 2018 Q4 | 12.32 Million SEK | 49.74% |
| 2018 Q2 | 4.77 Million SEK | 226.15% |
| 2017 FY | -5.59 Million SEK | 0.0% |
| 2017 Q2 | -21.34 Million SEK | -20425.96% |
| 2017 Q1 | -104 Thousand SEK | 0.0% |
| 2017 Q4 | -5.59 Million SEK | 52.36% |
| 2017 Q3 | -11.74 Million SEK | 44.97% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Acarix AB (publ) | -35.14 Million SEK | 67.535% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 100.93% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 100.93% |
| Arcoma AB | -1.12 Million SEK | -911.613% |
| Bactiguard Holding AB (publ) | 109.88 Million SEK | 110.385% |
| BICO Group AB (publ) | 927.9 Million SEK | 101.23% |
| Boule Diagnostics AB (publ) | 128.8 Million SEK | 108.859% |
| CellaVision AB (publ) | -56.94 Million SEK | 79.96% |
| Clinical Laserthermia Systems AB (publ) | -14.87 Million SEK | 23.298% |
| Chordate Medical Holding AB (publ) | -8.45 Million SEK | -34.958% |
| C-Rad AB (publ) | -127.6 Million SEK | 91.057% |
| Duearity AB (publ) | 10.23 Million SEK | 211.534% |
| Dignitana AB (publ) | 13.07 Million SEK | 187.26% |
| Episurf Medical AB (publ) | -52.7 Million SEK | 78.347% |
| Getinge AB (publ) | 5.4 Billion SEK | 100.211% |
| Scandinavian Real Heart AB (Publ) | -35.05 Million SEK | 67.447% |
| Iconovo AB (publ) | -10.75 Million SEK | -6.096% |
| Integrum AB (publ) | -10.47 Million SEK | -8.92% |
| Luxbright AB (publ) | -13.83 Million SEK | 17.512% |
| Mentice AB (publ) | -49.56 Million SEK | 76.977% |
| OssDsign AB (publ) | -162.78 Million SEK | 92.99% |
| Promimic AB (publ) | -50.32 Million SEK | 77.324% |
| Qlife Holding AB (publ) | 19.07 Million SEK | 159.837% |
| SciBase Holding AB (publ) | -27.32 Million SEK | 58.238% |
| ScandiDos AB (publ) | -1.53 Million SEK | -645.33% |
| Sectra AB (publ) | -772.85 Million SEK | 98.524% |
| Sedana Medical AB (publ) | -226.87 Million SEK | 94.97% |
| Senzime AB (publ) | -139.54 Million SEK | 91.822% |
| SpectraCure AB (publ) | -50.23 Million SEK | 77.284% |
| Stille AB | -178.5 Million SEK | 93.607% |
| Vitrolife AB (publ) | 1.22 Billion SEK | 100.929% |
| Xvivo Perfusion AB (publ) | -214.65 Million SEK | 94.684% |